添加LEA蛋白提高人未成熟卵母细胞体外成熟后玻璃化冷冻效率
本研究将两种LEA蛋白(AfrLEA2和AfrLEA3m)以10、100、200 µg/mL加入人未成熟卵母细胞体外成熟后的玻璃化冷冻-复苏液,发现100 µg/mL组线粒体膜电位显著高于对照组、活性氧和钙水平显著低于对照组,冰晶形成更小,可能通过下调FOS基因和减少氧化应激改善冻融卵母细胞发育潜能。
要点
- 100 µg/mL AfrLEA2或AfrLEA3m组线粒体膜电位显著高于对照组,活性氧和钙水平显著低于对照组。
- 100 µg/mL AfrLEA2或AfrLEA3m组冰晶形成小于DMSO和EG对照组,再结晶抑制优于常规冷冻保护剂。
- LEA蛋白可能通过下调FOS基因和减少氧化应激改善冻融人卵母细胞发育潜能。
核心结论
- LEA蛋白作为冷冻保护剂可改善人未成熟卵母细胞体外成熟后冻融的发育潜能,主要通过下调FOS基因、减少氧化应激和抑制冰晶形成。
研究设计与样本
- 将自行提取纯化的两种LEA蛋白以10、100、200 µg/mL加入人卵母细胞玻璃化冷冻-复苏液,确定每种蛋白的最佳保护浓度。
- 单个卵母细胞样本进行转录组分析,每组设三个样本重复。
- 未成熟卵母细胞取自接受体外受精(IVF)治疗且符合纳入排除标准的患者,经体外成熟(IVM)培养后用于实验研究。
主要发现
- AfrLEA2和AfrLEA3m蛋白二级结构含大量α螺旋且高度亲水,与既往报道一致。
- 免疫荧光显示AfrLEA2-FITC和AfrLEA3m-FITC标记蛋白呈细胞外分布,未穿透细胞膜,而FITC对照组不同。
- 100 µg/mL AfrLEA2或AfrLEA3m组细胞质颗粒较10和200 µg/mL组更均匀、空泡更少,最接近新鲜组。
- 100 µg/mL组线粒体膜电位显著高于对照组,活性氧和钙水平显著低于对照组,更接近新鲜卵母细胞水平。
- 100 µg/mL AfrLEA2或AfrLEA3m组在冰再结晶抑制试验中冰晶形成小于二甲基亚砜(DMSO)和乙二醇(EG)对照组,再结晶抑制优于常规冷冻保护剂DMSO和EG。
局限性
- 研究使用的体外成熟中期II(IVM-MII)卵母细胞受伦理限制,可能不能准确反映一般MII卵母细胞的状态。
- AfrLEA2和AfrLEA3m蛋白为重组蛋白,其合成稳定性需进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can the addition of late embryogenesis-abundant (LEA) proteins as a cryoprotective agent during the vitrification cryopreservation of in vitro matured oocytes enhance their developmental potential after fertilization? SUMMARY ANSWER: LEA proteins improve the developmental potential of human in vitro matured oocytes following cryopreservation, mostly by downregulating FOS genes, reducing oxidative stress, and inhibiting the formation of ice crystals. WHAT IS KNOWN ALREADY: Various factors in the vitrification process, including cryoprotectant toxicity, osmotic stress, and ice crystal formation during rewarming, can cause fatal damage to oocytes, thereby affecting the oocytes developmental potential and subsequent clinical outcomes. Recent studies have shown that LEA proteins possess high hydrophilicity and inherent stress tolerance, and can reduce low-temperature damage, although the molecular mechanism it exerts protective effects is still unclear. STUDY DESIGN, SIZE, DURATION: Two LEA proteins extracted and purified by us were added to solutions for vitrification-warming of oocytes at concentrations of 10, 100, and 200 µg/mL, to determine the optimal protective concentration for each protein. Individual oocyte samples were collected for transcriptomic analysis, with each group consisting of three sample replicates. PARTICIPANTS/MATERIALS, SETTING, METHODS: Immature oocytes were collected from patients who were undergoing combined in vitro fertilization (IVF) treatment and who had met the designated inclusion and exclusion criteria. These oocytes underwent in vitro maturation (IVM) culture for experimental research. A fluorescence microscope was used to detect the levels of mitochondrial membrane potential (MMP), reactive oxygen species (ROS), and calcium in the mitochondria of vitrified-warmed human oocytes treated with different concentrations of LEA proteins, and the protective effect of the protein on mitochondrial function was assessed. The levels of intracellular ice recrystallization inhibition (IRI) in human oocytes after vitrification-warming were characterized by the cryomicroscope, to determine the LEA proteins inhibitory effect on recrystallization. By analyzing transcriptome sequencing data to investigate the potential mechanism through which LEA proteins exert their cryoprotective effects. MAIN RESULTS AND THE ROLE OF CHANCE: The secondary structures of AfrLEA2 and AfrLEA3m proteins were shown to consist of a large number of α-helices and the proteins were shown to be highly hydrophilic, in agreement with previous reports. Confocal microscopy results showed that the immunofluorescence of AfrLEA2-FITC and AfrLEA3m-FITC-labeled proteins appeared to be extracellular and did not penetrate the cell membrane compared with the fluorescein isothiocyanate (FITC) control group, indicating that both AfrLEA2 and AfrLEA3m proteins were extracellular. The group treated with 100 µg/mL AfrLEA2 or AfrLEA3m protein had more uniform cytoplasmic particles and fewer vacuoles compared to the 10 and 200 µg/mL groups and were closest to the fresh group. In the 100 µg/mL groups, MMPs were significantly higher while ROS and calcium levels were significantly lower than those in the control group and were closer to the levels observed in fresh oocytes. Meanwhile, 100 µg/mL of AfrLEA2 or AfrLEA3m protein caused smaller ice crystal formation in the IRI assay compared to the control group treated with dimethylsulphoxide (DMSO) and ethylene glycol (EG); thus, the recrystallization inhibition was superior to that with the conventional cryoprotectants DMSO and EG. Further results revealed that the proteins improved the developmental potential of human oocytes following cryopreservation, likely by downregulating FOS genes and reducing oxidative stress. LIMITATIONS, REASONS FOR CAUTION: The in vitro-matured metaphase II (IVM-MII) oocytes used in the study, due to ethical constraints, may not accurately reflect the condition of MII oocytes in general. The AfrLEA2 and AfrLEA3m proteins are recombinant proteins and their synthetic stability needs to be further explored. WIDER IMPLICATIONS OF THE FINDINGS: LEA proteins, as a non-toxic and effective cryoprotectant, can reduce the cryoinjury of oocytes during cryopreservation. It provides a new promising method for cryopreservation of various cell types. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the National Key Research and Development Program of China (2022YFC2703000) and the National Natural Science Foundation of China (52206064). The authors declare no competing interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Li L, Bi X, Wu X, et al. Improving vitrification efficiency of human in vitro matured oocytes by the addition of LEA proteins. Hum Reprod. 2024. PMID: 38592717. doi:10.1093/humrep/deae065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。